Loading
Life sciences · Journal article
Obesity Science & Practice · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease is common in severe obesity; however, liver health assessment is inconsistently implemented in specialist weight management services and real‐world data are scarce. This study evaluated the prevalence and severity of vibration‐controlled transient elastography (VCTE)‐defined hepatic steatosis and fibrosis risk in adults attending a UK‐based Tier 3 specialist weight management service, and explored associations with clinical and metabolic characteristics. Methods This retrospective cross‐sectional study included 96 adults referred to a specialist weight management service who underwent baseline VCTE (FibroScan) between June 2024 and November 2025. Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) estimated hepatic steatosis and fibrosis risk, respectively. Demographic, anthropometric, clinical, and biochemical variables were extracted from electronic records. Generalized linear models identified factors associated with CAP and LSM, with sensitivity analyses adjusting for incretin‐based therapy use. Results Participants were predominantly female (83.3%) and White European (81.3%), with mean age 48.7 ± 12.5 years and BMI 42.0 ± 9.4 kg/m 2. VCTE‐defined steatosis was present in 82.3% (CAP ≥ 248 dB·m −1 ), with 57.3% classified as severe (CAP ≥ 280 dB·m‐ 1 ). Overall, 26.1% had elevated fibrosis risk (LSM ≥ 8 kPa), including 6.3% classified as high risk (LSM > 12 kPa). In multivariable analyses, higher BMI, HbA1c and ALT were independently associated with greater CAP, whereas BMI and HbA1c were independently associated with higher LSM. Further adjustment for incretin‐based pharmacotherapy use did not alter these relationships. Conclusions Hepatic steatosis and elevated fibrosis risk are highly prevalent in adults attending specialist weight management services. Adiposity and glycemic burden appear to be key determinants, supporting the integration of non‐invasive liver assessment into specialist obesity care pathways.